{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:48Z","timestamp":1792785048732,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Korean Society of Nephrology","id":[{"id":"https:\/\/ror.org\/01rncwg06","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fabry disease\u00a0(FD) is a rare X-linked lysosomal storage disorder associated with progressive multiorgan damage. Because perceptual differences between patients and clinicians regarding diagnosis and treatment can contribute to suboptimal management. We aimed to compare the perceptions of patients with FD and nephrologists in South Korea regarding the diagnostic process, treatment decisions, and genetic counseling. We conducted a cross-sectional survey enrolling 25 patients with FD, 33 patients with chronic kidney disease (without a known genetic etiology), and 27 nephrologists. The surveys assessed diagnostic testing considerations, treatment preferences, attitudes toward angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers (ACEi\/ARB), and genetic counseling priorities. All three groups prioritized diagnostic accuracy, while both patient groups emphasized procedural concerns (e.g., pain from blood draw and blood loss risk) significantly more than clinicians. A perception gap existed regarding ACEi\/ARB therapy: 92.3% of clinicians believed in its renoprotective effect, whereas only 26.1% of patients agreed to treatment without strong evidence. Both groups agreed on the importance of genetic counseling for family screening.\u00a0Regarding treatment, 96% of patients and 81.5% of clinicians preferred oral over injectable enzyme replacement therapy. These significant perception gaps highlight the need for improved patient education and shared decision-making to enhance treatment adherence and clinical outcomes in FD management.<\/jats:p>","DOI":"10.1038\/s41598-026-59734-x","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:38:02Z","timestamp":1782736682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perception and knowledge of Fabry disease: a comparative survey of patients and medical professionals in South Korea"],"prefix":"10.1038","volume":"16","author":[{"given":"Soo Jeong","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyang Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samel","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Seok","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Sil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hwan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hui","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Joo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Eun","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"59734_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain, D. P. Fabry disease. Orphanet J. Rare Dis. 5, 30. https:\/\/doi.org\/10.1186\/1750-1172-5-30 (2010).","journal-title":"Orphanet J. Rare Dis."},{"key":"59734_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng, C. M. et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J. Inherit. Metab. Dis. 30, 184\u2013192. https:\/\/doi.org\/10.1007\/s10545-007-0521-2 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"key":"59734_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada, M. et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79, 31\u201340. https:\/\/doi.org\/10.1086\/504601 (2006).","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"59734_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s13023-025-03707-2","volume":"20","author":"D Lee","year":"2025","unstructured":"Lee, D. et al. Current treatment status of Fabry disease in South Korea: A longitudinal National health insurance service data-based study. Orphanet J. Rare Dis. 20(1), 419. https:\/\/doi.org\/10.1186\/s13023-025-03707-2 (2025).","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"59734_CR5","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e63","volume":"34","author":"WS Kim","year":"2019","unstructured":"Kim, W. S. et al. Prevalence of Fabry disease in Korean men with left ventricular hypertrophy. J. Korean Med. Sci. 34(7), e63. https:\/\/doi.org\/10.3346\/jkms.2019.34.e63 (2019).","journal-title":"J. Korean Med. Sci."},{"key":"59734_CR6","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.26.150","author":"SH Kim","year":"2026","unstructured":"Kim, S. H. et al. Executive summary of evidence-based clinical practice guideline for Fabry nephropathy. Kidney Res. Clin. Pract. https:\/\/doi.org\/10.23876\/j.krcp.26.150 (2026).","journal-title":"Kidney Res. Clin. Pract."},{"key":"59734_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12914","volume":"71","author":"R Reisin","year":"2017","unstructured":"Reisin, R., Perrin, A. & Garc\u00eda-Pav\u00eda, P. Time delays in the diagnosis and treatment of Fabry disease. Int. J. Clin. Pract. 71, e12914. https:\/\/doi.org\/10.1111\/ijcp.12914 (2017).","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"59734_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1399-0004.2011.01718.x","volume":"81","author":"O Lidove","year":"2012","unstructured":"Lidove, O. et al. Fabry disease \u2018the new great imposter\u2019: Results of the French observatoire in internal medicine departments (FIMeD). Clin. Genet. 81(6), 571\u2013577. https:\/\/doi.org\/10.1111\/j.1399-0004.2011.01718.x (2012).","journal-title":"Clin. Genet."},{"key":"59734_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox, W. R. et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol. Genet. Metab. 93, 112\u2013128. https:\/\/doi.org\/10.1016\/j.ymgme.2007.09.013 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"59734_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","volume":"61","author":"R Thadhani","year":"2002","unstructured":"Thadhani, R. et al. Patients with Fabry disease on dialysis in the United States. Kidney Int. 61, 249\u2013255. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00097.x (2002).","journal-title":"Kidney Int."},{"key":"59734_CR11","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285, 2743\u20132749. https:\/\/doi.org\/10.1001\/jama.285.21.2743 (2001).","journal-title":"JAMA"},{"key":"59734_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain, D. P. et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 375, 545\u2013555. https:\/\/doi.org\/10.1056\/NEJMoa1510198 (2016).","journal-title":"N. Engl. J. Med."},{"key":"59734_CR13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock, D. G. et al. Antiproteinuric therapy and Fabry nephropathy: Factors associated with preserved kidney function during agalsidase-beta therapy. J. Med. Genet. 52, 860\u2013866. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103471 (2015).","journal-title":"J. Med. Genet."},{"key":"59734_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner, C. et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol. Genet. Metab. 124, 189\u2013203. https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.004 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"59734_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2025.101229","volume":"43","author":"EP McCarron","year":"2025","unstructured":"McCarron, E. P. et al. Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre. Mol. Genet. Metab. Rep. 43, 101229. https:\/\/doi.org\/10.1016\/j.ymgmr.2025.101229 (2025).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"59734_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.103742","volume":"11","author":"Y Battaglia","year":"2026","unstructured":"Battaglia, Y. et al. Dapagliflozin in patients with CKD with Fabry disease. Kidney Int. Rep. 11, 103742. https:\/\/doi.org\/10.1016\/j.ekir.2025.103742 (2026).","journal-title":"Kidney Int. Rep."},{"key":"59734_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.23876\/j.krcp.22.235","volume":"42","author":"SJ Choi","year":"2023","unstructured":"Choi, S. J. et al. A questionnaire survey on the diagnosis and treatment of Fabry nephropathy in clinical practice. Kidney Res. Clin. Pract. 42, 628\u2013638. https:\/\/doi.org\/10.23876\/j.krcp.22.235 (2023).","journal-title":"Kidney Res. Clin. Pract."},{"key":"59734_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13023-019-1254-7","volume":"14","author":"E No\u00ebl","year":"2019","unstructured":"No\u00ebl, E. et al. Treatment needs and expectations for Fabry disease in France: Development of a new patient needs questionnaire. Orphanet J. Rare Dis. 14, 284. https:\/\/doi.org\/10.1186\/s13023-019-1254-7 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"59734_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100808","volume":"1","author":"SC Rohani-Montez","year":"2023","unstructured":"Rohani-Montez, S. C. et al. Educational needs in diagnosing rare diseases: a multinational, multispecialty clinician survey. Genet. Med. Open 1, 100808. https:\/\/doi.org\/10.1016\/j.gimo.2023.100808 (2023).","journal-title":"Genet. Med. Open"},{"key":"59734_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-024-03090-4","volume":"19","author":"L Berry","year":"2024","unstructured":"Berry, L. et al. Patient-reported experience with Fabry disease and its management in the real-world setting: results from a double-blind, cross-sectional survey of 280 respondents. Orphanet J. Rare Dis. 19, 153. https:\/\/doi.org\/10.1186\/s13023-024-03090-4 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"59734_CR21","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s12325-019-01061-x","volume":"36","author":"O Morand","year":"2019","unstructured":"Morand, O. et al. Symptoms and quality of life in patients with Fabry disease: Results from an international patient survey. Adv. Ther. 36, 2866\u20132880. https:\/\/doi.org\/10.1007\/s12325-019-01061-x (2019).","journal-title":"Adv. Ther."},{"key":"59734_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100909","volume":"33","author":"M Tsurumi","year":"2022","unstructured":"Tsurumi, M., Ozaki, A. & Eto, Y. A survey on the patient journey in Fabry disease in Japan. Mol. Genet. Metab. Rep. 33, 100909. https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100909 (2022).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"59734_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100899","volume":"32","author":"N Inagaki","year":"2022","unstructured":"Inagaki, N., Tsuchiya, M., Otani, K. & Nakayama, T. Shared decision making between patients with Fabry disease and physicians in Japan: An online survey. Mol. Genet. Metab. Rep. 32, 100899. https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100899 (2022).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"59734_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","volume":"117","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin, R. J. et al. The management and treatment of children with Fabry disease: A United States-based perspective. Mol. Genet. Metab. 117, 104\u2013113. https:\/\/doi.org\/10.1016\/j.ymgme.2015.10.007 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"59734_CR25","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders, M. & Brand, E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J. Am. Soc. Nephrol. 29, 2265\u20132278. https:\/\/doi.org\/10.1681\/ASN.2018030329 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"59734_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1666","volume":"9","author":"DP Germain","year":"2021","unstructured":"Germain, D. P. et al. The benefits and challenges of family genetic testing in rare genetic diseases\u2014Lessons from Fabry disease. Mol. Genet. Genomic Med. 9, e1666. https:\/\/doi.org\/10.1002\/mgg3.1666 (2021).","journal-title":"Mol. Genet. Genomic Med."},{"key":"59734_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ndt\/gfaa324","volume":"37","author":"A Nagata","year":"2021","unstructured":"Nagata, A. et al. Screening of Fabry disease in patients with chronic kidney disease in Japan. Nephrol. Dial. Transplant. 37, 115\u2013125. https:\/\/doi.org\/10.1093\/ndt\/gfaa324 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"59734_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.23876\/j.krcp.22.087","volume":"43","author":"E Cho","year":"2024","unstructured":"Cho, E. et al. Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea. Kidney Res. Clin. Pract. 43, 71\u201381. https:\/\/doi.org\/10.23876\/j.krcp.22.087 (2024).","journal-title":"Kidney Res. Clin. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59734-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:01:48Z","timestamp":1790290908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59734-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59734"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59734-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. This study was approved by and received a waiver for the need for informed consent from the Institutional Review Board of Soonchunhyang University Bucheon Hospital (No. 2023-02-020). Participation was voluntary, and completion of the questionnaire was considered to imply informed consent. The survey was conducted anonymously, and no identifiable personal data were collected.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"29799"}}